Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
For the full year 2024, the Company expects total worldwide revenue to be between $78.0 million and $80.0 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 USD | +1.65% | -10.19% | -36.21% |
05-15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
05-14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
1st Jan change | Capi. | |
---|---|---|
-36.21% | 54.6M | |
+4.79% | 217B | |
+7.32% | 191B | |
+28.02% | 154B | |
+32.95% | 112B | |
+1.29% | 62.75B | |
+16.75% | 53.34B | |
+0.94% | 48.88B | |
-3.44% | 39.36B | |
+3.00% | 35.73B |